FK506 is an immunosuppressant drug in Phase III clinical trial.
The aim of this research is to investigate the pharmacokinetics of this drug, and the potential of drug/drug interactions, as well as the toxicity and activity of the metabolites of FK506.
Showing the most recent 10 out of 630 publications